Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003-2004 season - 09/08/11
, Matthew F. Daley, MD, Lori A. Crane, PhD, MPH, Jennifer Barrow, MSPH, Brenda L. Beaty, MSPH, Norma Allred, MSN, PhD, Stephen Berman, MD, Allison Kempe, MD, MPH
Reprint requests: Mandy A. Allison, MD, University of Utah, Division of General Pediatrics, 50 North Medical Drive 2A200 SOM, Salt Lake City, UT 84132.Résumé |
Objective |
To assess the clinical effectiveness of influenza vaccine in preventing influenza-like illness (ILI) office visits.
Study design |
We analyzed billing and immunization registry data for healthy 6- to 21-month-olds from 5 Denver, Colorado pediatric practices (n = 5193). ILI and pneumonia/influenza (a subset of ILI) were defined from International Classification of Diseases, Ninth Revision, Clinical Modification codes for office visits occurring during peak influenza season. Partially vaccinated (PV) and fully vaccinated (FV) patients were defined as having 1 shot and 2 shots, respectively, more than 14 days before the first ILI visit. The likelihood of an ILI visit was determined using a Cox proportional hazards model accounting for patient characteristics, practice site, and immunization status.
Results |
A total of 28% of the patients had an ILI office visit, and 5% had a pneumonia/influenza visit. Hazard ratios (HRs) for FV versus UV were 0.31 (95% confidence interval [CI] = 0.3 to 0.4) for ILI and 0.13 (95% CI = 0.1 to 0.2) for pneumonia/influenza, corresponding to a vaccine effectiveness (1 – HR × 100) of 69% for ILI and 87% for pneumonia/influenza. The corresponding HRs for PV versus UV were 1.0 (95% CI = 0.9 to 1.2) and 1.1 (95% CI = 0.8 to 1.5).
Conclusions |
Although 2 doses of vaccine were 69% effective against ILI office visits and 87% effective against pneumonia/influenza office visits, 1 dose did not prevent office visits during the 2003-2004 influenza season.
Le texte complet de cet article est disponible en PDF.Abbreviations : ACIP, CDC, CDPHE, CPT, FV, HMO, HR, ICD-9-CM, ILI, PV, RSV, UV
Plan
| Funding for this project was provided by a cooperative agreement with the Centers for Disease Control and Prevention (CDC) through the Association of American Medical Colleges (AAMC) (grant MM-0752-04/04). The contents of this report are solely the responsibility of the authors and do not necessarily represent the official views of the CDC or the AAMC. Dr. Allison was also supported by a National Research Service Award (grant T32 HP10006). |
Vol 149 - N° 6
P. 755 - décembre 2006 Retour au numéro
Article précédent
- Pharmacologic treatment of hypertension in children and adolescents
- Joseph T. Flynn, Stephen R. Daniels
- Fifty years ago in the Journal of Pediatrics : The relationship of paranatal experiences to oxygen saturation in newborn infants
- Neil N. Finer
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?